整理 | GLP1减重宝典内容团队 今日，慢性病创新疗法研发公司派格生物在港交所上市。 派格生物今日开盘报13.00港元/股，市值50.17亿港元。 此前，2024年11月13日，派格生物（PegBio Co., Ltd.）再次提交了更新版的IPO招股书，此前公司已于2024年2月23日首次向香港联交 所递交了IPO申请。 2023年6月，派格生物的估值约为40亿元人民币。 派格生物成立于2008年，总部位于江苏省苏州市，专注于慢性病创新疗法的研发，特别是在代谢紊乱领域。公司已自主研发出一款核心 产品，并拥有五款候选药物，涵盖2型糖尿病（T2DM）、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片类药物引起的便秘（OIC）、 先天性高胰岛素血症等常见慢性病及代谢疾病。 此外，派格生物的临床阶段候选药物包括PB-718，用于减重及降低肝脏脂肪含量；PB-1902，中国唯一一款针对阿片类药物引起的便秘 的口服型临床试验药物；PB-722，用于治疗先天性高胰岛素血症，并已获得FDA孤儿药资格认定。公司还在临床前阶段开发PB-2301， 针对T2DM、NASH和肥胖症的GLP-1/GIP双受体激动剂；PB-2309，针对 ...

Core Viewpoint - The article emphasizes the importance of healthy eating and balanced diet in weight management, highlighting the need for a three-year action plan to address the rising obesity rates in China [9][11]. Group 1: Dietary Recommendations - The official dietary guidelines recommend daily intake of at least 300 grams of fresh vegetables, with dark vegetables making up over 50% of that amount, and 200 to 350 grams of fresh fruits [6]. - Adults are advised to consume 50 to 100 grams of whole grains daily, ensuring at least one meal per day includes whole grains [6]. - It is suggested to eat fish, shrimp, and shellfish 1 to 2 times a week, with a weekly intake of 300 to 500 grams for adults [8]. Group 2: Weight Management Strategies - The National Health Commission reports that the overweight and obesity rate among adults in China has reached 51.2%, potentially exceeding 70% by 2030 if not controlled [9]. - Maintaining an energy deficit is crucial, meaning calorie intake should be less than calorie expenditure, but this does not require extreme dietary restrictions [9][11]. - A diverse diet is essential, with a minimum of 12 different food types daily and over 25 weekly, alongside a balanced nutritional ratio [11]. Group 3: Nutritional Supplements - Nutritional supplements are becoming popular, but experts advise against replacing meals with them, as nutrients from food are generally better absorbed and have fewer side effects [12]. - Long-term excessive intake of certain nutrients may pose health risks, and it is not recommended for healthy adults to indiscriminately supplement vitamins and minerals [14].

Core Viewpoint - Tirzepatide is a GIP/GLP-1 dual-target drug that shows significant efficacy in glycemic control and weight loss, outperforming Semaglutide in clinical studies [1][3][4]. Group 1: Unique Dual-Target Mechanism - Tirzepatide is the first and only approved glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, simulating the effects of both hormones [3]. - The drug exhibits a synergistic effect through the complementary actions of GIP and GLP-1, leading to enhanced therapeutic outcomes [1][3]. Group 2: Glycemic Control - Clinical studies indicate that Tirzepatide significantly reduces HbA1c levels in type 2 diabetes patients, with an average reduction of 2.0%-2.5% [4]. - In head-to-head studies, Tirzepatide demonstrated superior HbA1c reduction compared to Semaglutide, with a notable reduction of 2.46% in the 15mg group versus 1.86% in the 1mg Semaglutide group [4]. Group 3: Weight Loss Efficacy - In the SURMOUNT-5 trial, patients treated with Tirzepatide lost an average of 50.3 pounds (22.8 kg), significantly more than the 33.1 pounds (15.0 kg) lost by those on Semaglutide, representing a 47% greater weight loss [4]. - The Tirzepatide group achieved an average weight loss of 20.2%, compared to 13.7% in the Semaglutide group [4]. Group 4: Appetite Suppression - Tirzepatide optimizes neural signaling in the brain's appetite control centers, enhancing satiety signals and reducing food intake without relying on willpower [5]. - The drug effectively delays gastric emptying, prolonging food retention in the stomach and reducing hunger frequency [8][10]. Group 5: Metabolic Benefits - Tirzepatide increases basal metabolic rate and promotes energy expenditure, aiding in weight loss even at rest [11]. - The drug improves insulin sensitivity and pancreatic beta-cell function in type 2 diabetes patients, contributing to better blood sugar control [11]. Group 6: Sustained Weight Loss - Clinical data from the SURMOUNT-1 study showed that Tirzepatide led to significant weight loss over 176 weeks, with reductions of 15.4% to 22.9% depending on dosage, compared to only 2.1% in the placebo group [12]. - The SURMOUNT-2 study confirmed that higher doses of Tirzepatide resulted in an average weight loss of 15.7% (15.6 kg) over 72 weeks [14]. Group 7: Regulatory Approval - Based on the positive outcomes from SURMOUNT-1 and SURMOUNT-2, the FDA approved Tirzepatide for obesity treatment in November 2023 [15].

整理 | GLP1减重宝典内容团队 无论是借助有效的新药减肥，还是通过减肥手术减肥，或是减少卡路里摄入并增加运动，总有一天体重秤上的数字会停止下降，这时会进入无 奈的减重平台期。 研究表明， 胃绕道手术和 Wegovy、Zepbound 等新型减肥药之所以如此有效，部分原因是它们使进入平台期的时间增加了一倍。没有药物和 手术干预，进入平台期平均时间为一年，药物和手术干预使进入平台期延缓了一年。与单纯减少卡路里摄入相比，人们能够更长时间地减肥。 ▍ 为什么出现减重平台期 身体通过试图保持摄入的卡路里和燃烧的卡路里之间的平衡来调节体重。当我们消耗或减少卡路里，并开始燃烧储存的能量时，食欲就会开始 告诉我们要吃更多。 研究表明，一个人减掉的体重越多，食欲就会越强 ，直到抵消甚至完全抵消他们最初为减肥所做的所有努力。 体重平台期的出现，主要源于基础代谢率的下降。 当体重减少大约5公斤时，人体的基础代谢率会自动下调。一旦基础代谢率下降，身体就会 重新进入能量储存模式，不再响应减重需求，从而导致体重停滞不降。 体重调定点理论指出，人体体重存在一个"自然调定点" ，身体会通过调节代谢率和饥饿感来维持体重在这个平衡点附近10 ...

Core Viewpoint - A large-scale study published in JAMA Internal Medicine suggests that certain diabetes medications may reduce the risk of acute exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D) and active COPD [2][6]. Research Overview - The study analyzed data from three major insurance claims databases in the U.S. from 2013 to 2023, using a propensity score-matched cohort design to compare the risk of COPD exacerbations among patients aged 40 and older receiving SGLT-2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors [3][4]. Key Findings - Among 393,847 patients, the matched cohorts included 27,991 pairs for SGLT-2i vs. DPP-4i, 32,107 pairs for GLP-1RA vs. DPP-4i, and 36,218 pairs for SGLT-2i vs. GLP-1RA. The median follow-up period was 145 days, revealing: - SGLT-2i showed a lower risk of COPD exacerbation compared to DPP-4i (9.26 vs. 11.4 per 100 person-years; HR: 0.81; IRD: -2.20) [4]. - GLP-1RAs also demonstrated a lower risk compared to DPP-4is (9.89 vs. 11.49 per 100 person-years; HR: 0.86; IRD: -1.60) [4]. - The difference in acute exacerbation risk between SGLT-2is and GLP-1RAs was minimal (9.47 vs. 10.00 per 100 person-years; HR: 0.94; IRD: -0.55) [5]. Clinical Significance - The findings indicate that SGLT-2is and GLP-1RAs may be superior to DPP-4is for patients with both T2D and COPD, potentially guiding future treatment decisions for this population. The study highlights the potential benefits of these medications beyond glycemic control, particularly for patients managing both conditions [6][8]. Limitations - The study is observational in nature and may have residual confounding factors. Further randomized controlled trials are needed to confirm these findings and explore the mechanisms by which these medications reduce the risk of COPD exacerbations [7].

大众的体重管理意识正在逐步提升。数据显示，约一半的人自认为存在超重风险，七成人已经具备体重管理意识并希望改善体重状况，超过六 成愿意为控制体重投入时间和精力，积极参与各类体重管理行动。 2025年5月10日，《成人健康体重管理白皮书（2025）》在第二届中国肥胖防控大会上正式发布。此次白皮书的推出，旨在推动社会更加重视 科学健康的减重方式。 据悉，这本白皮书由中华预防医学会联合暨南大学等机构，基于对公众体重管理实际情况的调研共同编写。内容涵盖了大众对体重管理的认知 与意识、实际行动举措以及未来的期望等多个方面。 国家卫生健康委发布的《体重管理指导原则（2024年版）》显示，目前我国成年人的超重率为34.3%，肥胖率为16.4%。如果不采取有效措施， 到2030年，成人超重和肥胖率预计将升至70.5%。与此同时，2030年因超重和肥胖带来的医疗费用预计高达610亿美元，占全国医疗卫生支出的 22%。 本更管理 国家卫生健康委员会 National Health Commission of the People's Republic of China 官方发布! 最新版25条"体重管理"措施来了, 文速查 中华预 ...

Group 1 - The core viewpoint of the article is that Aimeike (300896.SZ) is currently in the clinical trial phase for its "Semaglutide Injection" project [1]. Group 2 - The article mentions that the "GLP-1 Club" consists of hundreds of professionals and serves as a primary choice for industry experts to gain insights into the GLP-1 industry chain [6]. - The club offers various resources such as lectures, academic promotions, and consulting services to its members [7].

Core Viewpoint - Obesity is a health condition associated with excess fat accumulation, leading to various complications and comorbidities. GLP-1 receptor agonists have been developed and approved for obesity treatment, demonstrating effectiveness in appetite reduction and weight loss [1][2][4]. Summary by Sections Treatment Efficacy - GLP-1 receptor agonists, such as semaglutide and tirzepatide, have shown weight loss of 15%-20% after 68 to 72 weeks compared to placebo [2]. - A clinical trial indicated that participants lost an average of 10.6% of their body weight during 20 weeks of semaglutide treatment, with those continuing the drug losing an additional 7.9% over 48 weeks [5]. Challenges in Weight Maintenance - One of the biggest challenges in weight loss is maintaining the results, as many individuals experience weight regain after stopping treatment. Studies show that stopping GLP-1 receptor agonists can lead to significant weight gain [4][5]. - After one year of stopping semaglutide, approximately two-thirds of the weight lost can be regained [5]. Medication Management - It is recommended to continue GLP-1 receptor agonist treatment for at least 12 weeks to see significant effects, with a suggested continuation of 9 months to 1 year for consolidation [6]. - Users may experience increased satiety and reduced food intake initially, with weight loss typically ranging from 0.5 to 2 pounds per week [9]. Discontinuation Strategies - Gradual dose reduction is advised when stopping the medication to mitigate increased hunger, with specific recommendations for both non-diabetic and diabetic patients [10][12]. - Maintaining healthy eating habits and regular exercise is crucial post-discontinuation to prevent weight rebound [12]. Dietary and Lifestyle Recommendations - Key strategies to prevent weight regain include altering dietary habits by reducing high-calorie foods and increasing protein and fiber intake [13]. - Incorporating strength training and ensuring adequate sleep (7-9 hours per night) are also essential for maintaining weight loss and improving metabolic health [15].

Core Viewpoint - The Chinese government has initiated a national "Weight Management Year" action plan to combat the rising obesity rates, emphasizing that this is a public health issue rather than just a personal choice [3][4]. Group 1: Obesity Crisis - China's overweight and obesity rates have surged 12 times in the past 15 years, leading to significant health and economic consequences [4][6]. - As of 2021, nearly 2.6 billion people globally are overweight or obese, with a dramatic increase of 188% in adults and 149% in youth since 1990 [4][5]. - The direct medical costs associated with obesity in China exceed 240 billion yuan, highlighting the financial burden on the healthcare system [6]. Group 2: Global Responses - Various countries have implemented unique strategies to address obesity, such as the UK's sugar tax, which has led to a significant reduction in sugary drink sales [8]. - The Netherlands has adopted a dual approach of treatment and prevention for obesity, focusing on personalized care for different demographics [9]. - Spain's national strategy aims to reduce childhood obesity through increased physical activity and nutrition education [10]. Group 3: Economic Implications - Obesity is linked to economic disparities, with wealthier individuals often having better access to healthy food options, while lower-income communities face higher rates of obesity due to cheaper, unhealthy food choices [15][16]. - The healthcare costs associated with obesity are projected to strain China's medical insurance system, with over 70% of adults expected to be overweight by 2030 [6][15]. Group 4: Domestic Initiatives - The Chinese government is implementing localized measures to promote healthier eating habits, such as reducing oil and salt in popular dishes and encouraging lighter food options on delivery platforms [16][17]. - Schools are taking proactive steps to limit unhealthy snacks near campuses, aiming to combat childhood obesity from an early age [17].

整理 | GLP1减重宝典内容团队 联邦政府已正式终止非品牌减肥药和糖尿病药物的销售，切断了依赖这些药物的患者获取药物的渠道。 据 CNN 报道，美国食品药品监督管理局 (FDA) 最近宣布，广泛使用的 GLP-1 药物的供应短缺问题已得到解决。这些药物包括司美格鲁肽 （商品名 Ozempic 和 Wegovy）以及替泽帕肽（商品名 Mounjaro 和 Zepbound）。 根据此次更新，FDA 不再允许未经机构批准生产或销售这些药物的复方制剂。复方制剂通常由小型药房生产，并在药物短缺期间用于满足需 求。 "我们必须对患者诚实，"弗里茨勒表示。"在过去三个月里，我们优先考虑那些有需要的患者，以便在截止日期前尽可能多地帮助他们。许多 人担心无法获得药物。" 其中一位患者是来自德克萨斯州的25岁米歇尔·皮尔斯（Michelle Pierce）。她说，复方司美格鲁肽帮助她降低了血糖，并避免了背部手术。 现在，她说："我真的没有其他选择了。我绝对负担不起自付费用。" 虽然复方司美格鲁肽是一种成本更低的替代方案，但一些医疗专业人士提出了安全方面的担忧。 "你们没有FDA那样可靠的监管，"波士顿贝斯以色列女执事医疗中心 ...